Call us Toll-Free
800-476-6070

Weitz & Luxenberg Facebook Weitz & Luxenberg Google Weitz & Luxenberg Twitter Weitz & Luxenberg LinkedIn
English En Français

FREE LEGAL REVIEW

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
Were you diagnosed with lung cancer? Yes
Were you diagnosed with Mesothelioma? yes
What is your date of diagnosis?
Additional Comments
Best time to call?

Mesothelioma Publication - Heparanase

This is an abstract of an article about heparanase and mesothelioma published at PubMed by the NIH.

Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.

Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R.
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway. bend@ulrik.uio.no
Clin Exp Metastasis. 2004;21(5):469-76.

Heparanase is an endoglycosidase that degrades heparan sulfate (HS) in the extracellular matrix (ECM) and cell surfaces, and fulfills a significant role in cancer metastasis and angiogenesis.

We evaluated the expression of heparanase and its possible association with the expression of angiogenic molecules in malignant mesothelioma (MM), and analyzed whether expression of these proteins is site-related (pleural vs peritoneal MM, solid lesions vs effusions). Sections from 80 MM (56 biopsies, 24 effusions) were analyzed for heparanase protein expression using immunohistochemistry (IHC).

Sixty MM were of pleural origin, and 20 were peritoneal. Effusion specimens consisted of 6 peritoneal and 18 pleural effusions, while biopsies consisted of 14 peritoneal and 42 pleural lesions. Fifty-four specimens were additionally evaluated for expression of basic fibroblast growth factor (bFGF), interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) proteins using IHC. Microvessel density (MVD) was studied in 28 biopsies using an anti-CD31 antibody. mRNA expression of heparanase (HPSE-1), VEGF and the VEGF receptor KDR was analyzed in 23 effusions using RT-PCR.

Heparanase protein expression was seen in 69/80 (86%) tumors. Of these, 35 showed combined membrane and cytoplasmic expression, 30 cytoplasmic expression, and four exclusively membrane expression. Both total (P = 0.001) and cytoplasmic (P = 0.002) expression was significantly higher in solid tumors compared to effusions. Protein expression of VEGF, IL-8 and bFGF was seen in 21/54 (39%), 22/54 (41%) and 44/54 (81%) specimens, respectively. Protein expression of bFGF was significantly higher in solid tumors (P < 0.001) and correlated with heparanase expression (P = 0.005). HPSE-1 and VEGF mRNA expression was detected in all 23 effusions using RT-PCR, while KDR mRNA was found in 12/23 MM. KDR mRNA expression correlated with that of both HPSE-1 (P = 0.005) and VEGF (P = 0.001).

Our results document frequent expression of heparanase in MM, in agreement with the biological aggressiveness of this tumor. The co-expression of heparanase with bFGF is in agreement with the role of the former in releasing bFGF from the ECM. The concomitant reduction in protein expression of both molecules in effusions as compared to solid tumors, supports the hypothesis of a reduced need for pro-angiogenic stimuli in effusions, and may aid in defining tumor progression in this setting.

Exposure to asbestos is known to cause serious illnesses such as mesothelioma, asbestos-related lung cancer or asbestosis.

If you or a loved one has been diagnosed with an asbestos illness, contact our lawyers today for a free review of your case. A Weitz & Luxenberg representative will contact you as soon as possible.

Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos
Real Stories


Mesothelioma
Mesothelioma Resource Center
Mesothelioma
Information about Diagnosis
Latest News
IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Mesothelioma in Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Mesothelioma Pathogenesis
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

Mesothelioma Lawyer

Asbestos Lawyer

Mesothelioma Attorney

Asbestos Attorney

Mesothelioma Treatment

see also:

Farnesyltransferase Inhibitors Learn about mesothelioma and farnesyltransferase inhibitors
Mesothelioma lawyers provide info about Farnesyltransferase inhibitors

ThinPrep Cytospin ThinPrep Cytospin | Weitz & Luxenberg
An abstract of an article about Mesothelioma and ThinPrep Cytospin

National Mesothelioma Publications The National Institute of Health mesothelioma research publications
Mesothelioma publications from the National Institute of Health